384.95
+15.11(+4.09%)
Currency In USD
Previous Close | 369.84 |
Open | 354.56 |
Day High | 386.05 |
Day Low | 351.32 |
52-Week High | 386.05 |
52-Week Low | 200.63 |
Volume | 549,822 |
Average Volume | 357,093 |
Market Cap | 8.58B |
PE | -30.43 |
EPS | -12.65 |
Moving Average 50 Days | 309.78 |
Moving Average 200 Days | 313.96 |
Change | 15.11 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $5,082.42 as of August 18, 2025 at a share price of $370. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $3,395.12 as of August 18, 2025 at a share price of $370.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 11, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
GlobeNewswire Inc.
Jul 30, 2025 9:00 AM GMT
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
GlobeNewswire Inc.
Jul 25, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today th